Back to stock research

Verified earnings summary

Research updated: Jul 12, 2026, 12:00 AM UTC

BDX FY2026 Q2

BD's fiscal second-quarter 2026 update reflected demand across medication delivery, diagnostics and interventional products while the company continued portfolio-separation work and productivity initiatives.

This page provides a source-verified release summary. It does not display a normalized metric table or post-earnings market reaction until those fields are independently verified.

Constructive signals after the release

  • A broad installed base supports repeat demand for needles, syringes, diagnostic consumables and medication-management supplies.
  • New pharmacy automation, microbiology and interventional products can improve mix and customer workflows.
  • A focused separation can simplify the remaining business and sharpen capital allocation if executed cleanly.

Risks that still need monitoring

  • Separation complexity

    Carve-out costs, stranded overhead and operational disruption could dilute expected portfolio benefits.

  • Quality and regulatory risk

    Medical-device recalls, remediation or regulatory findings can interrupt supply and raise costs.

  • Hospital budget pressure

    Provider labor and capital constraints can delay equipment upgrades and pressure pricing.

Primary sources

BD Reports Second Quarter Fiscal 2026 Financial ResultsBecton, Dickinson and Company · earningsVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 5/7/2026, 12:00:00 AM

Open original source
Becton, Dickinson and Company Investor RelationsBecton, Dickinson and Company · companyVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Open original source
BD SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 5/7/2026, 12:00:00 AM

Open original source

Continue research

Open risk researchReturn to full stock research